期刊文献+

二甲双胍对2型糖尿病患者的心血管保护作用:证据及其潜在机制 被引量:13

Protective cardiovascular effects of metformin in type 2 diabetic patients: evidence and underlying mechanisms
原文传递
导出
摘要 二甲双胍是治疗2型糖尿病的一线药物。二甲双胍除了具有理想的降糖作用外,还具有一定的心血管保护效应.其中包括预防动脉粥样硬化的发生和发展、降低心血管事件风险、减轻心肌缺血一再灌注损伤、抑制心肌重构、延缓心力衰竭进展等。激活腺苷酸活化的蛋白激酶(AMPK)信号通路在二甲双胍的心血管保护作用中起着至关重要的作用。 Metformin has been recommended as the first-line therapy for type 2 diabetes. Besides its ideal glucose-lowering effect, metformin has also been shown to exert beneficial effects on cardiovascular system, including preventing the occurrence and progression of atherosclerosis, reducing risk for cardiovascular events, attenuating myocardial ischemia-reperfusion injury, improving ventricular remodeling, and slowing the progress of heart failure. The activation of adenosine monophosphate activated protein kinase (AMPK) signaling pathway plays a pivotal role in the protective cardiovascular effects resulted from metformin.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2013年第9期735-739,共5页 Chinese Journal of Endocrinology and Metabolism
基金 国家973计划资助项目(2012CB517502) 教育部博士点科研基金资助项目(20120001120069,20100001110083) 国家自然科学基金资助项目(81070701,81270858)
关键词 二甲双胍 糖尿病 2型 心血管事件 心力衰竭 腺苷酸活化的蛋白激酶 Metformin Diabetes mellitus, type 2 Cardiovascular events Heart failure Adenosine monophosphate activated protein kinase
  • 相关文献

参考文献44

  • 1Cusi K, Consoli A, De Fronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endoerinol Metab, 1996,81:4059-4067.
  • 2] UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose eontrol with metfofin on complications in overweight patients with type 2 diahetes ( UKPDS 34 ). Lancet, 1998,352 : 854- 865.
  • 3Holman RR, Paul SK, Bethel MA, glucose control in type 2 diabetes. et al. 10-year follow-up of intensive N Engl J Med, 2008,359: 1577-1589.
  • 4Kao J, Tobis J, McClelland RL, et al. Relation of methmnin treatmen! to clinical events in diabetic patients undergoing pereutaneous intervention. Am J Cardiol, ?.004,93 : 1347-1350.
  • 5Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with diffbrent insulin secretagogues compared with metfurmin in type 2 diabetes, with or without a previuus myocardial infarction: A nationwide study. Eur Heart J, 2011,32: 1900-1908.
  • 6Hong J, Zhang Y, Lai S, et al. Effects of mettormin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary arte disease. Diabetes Care, 2013,36 : 1304-1311.
  • 7Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, mefformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation, 2005,111:583-590.
  • 8Eurieh DT, Majumdar SIR, Me Alister FA, et al. Improved elinieal outcomes associated with mefformin in patients with diabetes and heat failure. Diabetes Care, 2005,28 : 2345-2351.
  • 9Shah DD, Fonarow GC, Horwieh TB. Metformin therapy and outcomes in patients with advanced systolic heart liailure and diahetes. J Card Fail, 2010,16:200-206.
  • 10Saenz A, Femandez-Esteban I, Mataix A, et al. Metformin monoth- erapy for type 2 diabetes mellitus. Coehrane Database Syst Rev, 2005, CD002966.

同被引文献142

引证文献13

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部